Previous Article | Next Article 
Journal of Clinical Microbiology, June 2001, p. 2356-2357, Vol. 39, No. 6
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.6.2356-2357.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Bacteremia by Dermabacter hominis, a
Rare Pathogen
José Luis
Gómez-Garcés,1,*
Jesús
Oteo,1
Guadalupe
García,1
Belén
Aracil,1
Juan Ignacio
Alós,1 and
Guido
Funke2
Servicio de Microbiologia, Hospital de
Mostoles, Madrid, Spain,1 and Department
of Medical Microbiology, Gärtner and Colleagues Labs,
Weingarten, Germany2
Received 27 November 2000/Returned for modification 22 January
2001/Accepted 28 March 2001
 |
ABSTRACT |
Dermabacter hominis is a gram-positive,
catalase-positive, glucose-fermenting rod, which, as it grows forms
small greyish-white colonies with a characteristic pungent odor.
Previously known as coryneform Centers for Disease Control and
Prevention groups 3 and 5, it was catalogued as D. hominis
in 1994. Various strains isolated in blood cultures, abscesses, or
wounds in the 1970s were retrospectively characterized in referral
centers as D. hominis. In this report we describe two
patients with severe underlying pathology who developed bacteremias by
D. hominis within the context of their clinical pictures.
 |
CASE REPORTS |
Case 1.
A 29-year-old woman was
human immunodeficiency virus positive in stage B3 of AIDS. She was
admitted to our hospital with left hemiparesia. A cerebral computer
tomography scan showed a hypodense lesion in the left parietal lobe
compatible with progressive multifocal leukoencephalopathy. A
peripheral venous catheter was placed. While in the hospital the
patient suffered a marked deterioration of her neurological situation,
together with severe worsening of her general state, with alteration of
pulmonary function, upper digestive tract hemorrhage, and fever peaks.
Various antimicrobial therapies were administered, including
clindamycin, ciprofloxacin, and the combination of fluconazole,
meropenem, and sulfamethoxazole, in spite of the fact that no
pathogenic microorganism was isolated in the various cultures
requested, including the catheter culture. The patient's situation
worsened and reached terminal stage, which led to the decision to
suspend all medication and to maintain only sedation. Dermabacter
hominis and Candida albicans were isolated from two
blood cultures taken 48 h earlier. Treatment with fluconazole and
vancomycin was initiated, but the patient died 24 h later.
Case 2.
A 65-year-old male patient had a personal history of
cardiopathy and broncho-obstructive pneumopathy. He was brought to our Emergency Service with thoracic pain, for which he was admitted to the
Cardiology Department. While in the hospital he suffered a
cardiorespiratory arrest, from which he recovered after cardiopulmonary reanimation although he was left with irreversible neurological sequelae. During the following days he suffered episodes of fever peaks
for which antibiotic treatment with cloxacillin plus gentamicin was
administered. After 4 days without fever and without antibiotic treatment he presented with a febrile peak of more than 38°C. At this
point two blood cultures were taken and the catheter was removed for
culture. The patient's condition deteriorated, and he died
suddenly 48 h later. That same day D. hominis grew in the two blood cultures. The catheter culture was negative.
Microbiology.
In both patients small gram-positive
coccobacilli with a coryneform appearance were detected in two blood
cultures per patient, processed with the VITAL system
(bioMerieux, Marcy l'Etoile, France). These grew, after 24 h
of incubation in an atmosphere enriched with 5% CO2, in
the subcultures performed on blood agar plates. The colonies were small
and greyish-white with an intense and pungent odor. After 48 h the
size of the colonies increased to 1 mm in diameter.
The microorganisms were identified as D. hominis on account
of their phenotypic characteristics, which included the absence of
motility and negative reactions for urease, oxidase, and nitrate reduction. Among the positive reactions were catalase production and
esculin hydrolysis, and there was a fermentation pattern which included
the production of acid from glucose, sucrose, maltose, and lactose. In
addition, the bacteria decarboxylated lysine and ornithine.
Using the API Coryne system (bioMerieux) we obtained the numerical
profile 4570565, which in the API plus, version 2.0, database
corresponds to an "excellent identification" of
D. hominis.
In addition, the strains presented a composition of the cell wall which
was characterized by the absence of mycolic acids
and the presence of
m-diaminopimelic acid as the diaminoacid of
the
peptidoglycan.
As indicated by the method of diffusion gradient (E-test; Biodisc,
Solna, Sweden), the microorganism was potentially susceptible
to
various

-lactams, glycopeptides, and rifamicins and displayed
resistance to aminoglycosides, fluoroquinolones, macrolides, and
lincosamides. The MICs obtained for the different antimicrobial
agents
are as follows: penicillin, 2 mg/liter; cefuroxime, 8 mg/liter;
cefotaxime, 4 mg/liter; gentamicin, >256 mg/liter; erythromycin,
>256 mg/liter; clindamycin, >256 mg/liter; ciprofloxacin, >32
mg/liter; rifampin, 0.03 mg/liter; vancomycin, 0.25 to 0.5 mg/liter.
Discussion.
Until recently the isolation of coryneform
bacteria in clinical samples, especially in blood cultures, was usually
considered synonymous with contamination. In recent years, there has
been a progressive increase in the number of reports in the literature of clinical cases associated with the isolation of various coryneforms, and the number of convincingly documented descriptions of infections by
this group of agents has enriched our knowledge of this subject, especially in terms of a more precise and reliable microbiological diagnosis of the genera and species involved. This diagnosis would include an initial screening based on the production or lack of production of catalase, motility, and the fermentation or oxidation capacity of the strain. With these basic data as a starting point, the
use of commercial galleries (bioMerieux) provides a second stage, which
in many cases is sufficient for the identification of the
microorganism. Last, the quantitative and qualitative evaluations of
the fatty acids of the bacterial wall, chromatographic analysis of
mycolic acids, and, as a last resort, molecular-genetics techniques, in
most cases, provide a precise identification, although the last
techniques are only carried out in referral laboratories (3).
Dermabacter is a relatively new genus, and
D. hominis is a relatively new species (
2,
7).
D. hominis has been assigned
to those coryneforms previously
designated Centers for Disease
Control and Prevention groups 3 and 5, whose epidemiology, potential
pathogenic role, and antimicrobial
susceptibilities were unknown
until a decade ago (
4). This
lack of knowledge led to it being
left out of the database of the API
Code Book, version 1.0, and
its profiles (4470765, 4570165, 4570364, 4570365, and 4570765)
being ascribed to group A coryneforms
(
1). Little has been
learned since its description
concerning the epidemiology of this
agent, except that it appears to
form part of the human cutaneous
flora, and its role in clinical
pictures has not yet been defined
(
6). To date, very few
case reports of serious infections caused
by this agent have been
described (
2).
Possibly one of the factors, together with its recent systemic
assignation, that has contributed to our ignorance of the role
it may
play in infectious pathology is its broad profile of antimicrobial
susceptibility. The strains tested to date display susceptibility
to

-lactams and glycopeptides (
5), antibiotics very
frequently
used in empiric treatment of infections of unknown origin in
patients
with severe underlying pathologies, in which these
microorganisms
could play an important
role.
The patients described in this report had extremely severe underlying
pathologies. The first case involved AIDS in advanced
stage with severe
neurological effects, in the course of which
the patient presented
fever peaks treated empirically with a wide
range of antibiotics. These
antibiotics, without doubt, contributed
to the etiological selection of
the last septic episode, in which
C. albicans and
D. hominis were isolated in two pairs of blood
cultures. The second
patient, like the first, presented with severe
neurological effects.
The antibiotic treatment chosen to control
empirically a concomitant
episode of fever, gentamicin plus an
antistaphylococcal penicillin,
presumably served to develop the
final bacteremia by
D. hominis, isolates of which displayed resistance
to both
antibiotics.
In conclusion,
D. hominis may be placed in the large group
of human colonizers which, in patients with severe underlying diseases
and reduction of defensive capacity, take advantage of the
administration
of broad-spectrum antimicrobial therapies to develop
their virulence
opportunistically in these terminal stages. However, an
improved
knowledge of the characteristics of these microorganisms would
facilitate the description of the role which they play in the
infectious pathologies of our
times.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Servicio de
Microbiologia, Hospital de Mostoles, C/Rio Jucar s/n 28935 Mostoles,
Madrid, Spain. Phone and fax: 34/916648750. E-mail:
jlgarces{at}microb.net.
 |
REFERENCES |
| 1.
|
API Systems
1989.
API CORYNE analytical profile index.
API Systems, La-Balme-les-Grottes, France.
|
| 2.
|
Bavkent, M.,
H. Caner,
H. Arslan,
B. Demirhan,
S. Tuncbilek, and N. Altinors.
1998.
Cerebral Dermabacter hominis abscess.
Infection
26:181-183[Medline].
|
| 3.
|
Bernard, K.,
M. Bellefeuille,
D. G. Hollis,
M. I. Daneshvar, and C. W. Moss.
1994.
Cellular fatty acid composition and phenotypic and cultural characterization of CDC fermentative coryneform groups 3 and 5.
J. Clin. Microbiol.
32:1217-1222[Abstract/Free Full Text].
|
| 4.
|
Funke, G.,
S. Stubbs,
G. E. Pfyffer,
M. Marchiani, and M. D. Collins.
1994.
Characteristics of CDC group 3 and 5 coryneform bacteria isolated from clinical specimens and assignment to the genus Dermabacter.
J. Clin. Microbiol.
32:1223-1228[Abstract/Free Full Text].
|
| 5.
|
Funke, G.,
V. Pünter, and A. von Graevenitz.
1996.
Antimicrobial susceptibility patterns of some recently defined coryneform bacteria.
Antimicrob. Agents Chemother.
40:2874-2878[Abstract].
|
| 6.
|
Funke, G.,
A. von Graevenitz,
J. E. Clarridge III, and K. A. Bernard.
1997.
Clinical microbiology of coryneform bacteria.
Clin. Microbiol. Rev.
10:125-159[Abstract].
|
| 7.
|
Jones, D., and M. D. Collins.
1988.
Taxonomic studies on some human cutaneous coryneform bacteria: description of Dermabacter hominis gen. nov. sp. nov.
FEMS Microbiol. Lett.
51:51-56.
|
Journal of Clinical Microbiology, June 2001, p. 2356-2357, Vol. 39, No. 6
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.6.2356-2357.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Renvoise, A., Aldrovandi, N., Raoult, D., Roux, V.
(2009). Helcobacillus massiliensis gen. nov., sp. nov., a novel representative of the family Dermabacteraceae isolated from a patient with a cutaneous discharge. Int. J. Syst. Evol. Microbiol.
59: 2346-2351
[Abstract]
[Full Text]
-
Radtke, A., Bergh, K., Oien, C. M., Bevanger, L. S.
(2001). Peritoneal Dialysis-Associated Peritonitis Caused by Dermabacter hominis. J. Clin. Microbiol.
39: 3420-3421
[Abstract]
[Full Text]